

Ref: STEX/OUTCOME/2026-27

Date: 14.08.2026

BSE Limited 25th Floor Phiroze Jeejeebhoy Towers Dalal Street, Mumbai 400 001 BSE Code-531146	National Stock Exchange of India Limited Exchange Plaza, C-1, Block - G Bandra Kurla Complex Bandra (East) Mumbai - 400 051 NSE Code: MEDICAMEQ
--	---

Sub.: Outcome of Board Meeting

Dear Sir,

We wish to inform you that the Board of Directors of the Company at its meeting held today approved the **Unaudited Financial Results (Standalone and Consolidated)** of the Company for the quarter ended on June 30, 2026.

Pursuant to Regulation 30 & 33 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

- Statement showing the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter ended on June 30, 2026 as **Annexure-A**; and
- Limited Review Report on the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter ended on June 30, 2026 as **Annexure-B**.

Further, the Board of Directors at their meeting considered, approved and took note of the following matters:

- Approval of Draft Annual Report for the Financial Year 2025-26**

The Board approved the draft Annual Report of the Company for the financial year 2025-26.

- Approval of Draft Cost Audit Report for the Financial Year 2025-26**

The Board approved the draft Cost Audit Report of the Company for the financial year 2025-26.

PARUL
CHOUDHARY
Digitally signed
by PARUL
CHOUDHARY
Date: 2026.08.14
15:19:50 +05'30'



d) **33rd Annual General Meeting**

The Board approved that the **33rd Annual General Meeting of the Company will be held on Saturday, September 26, 2026 at 12.00 Noon** through Video Conferencing (VC)/Other Audio-Visual Means (OAVM) facility.

Pursuant to Rule 20(4)(vii) of the Companies (Management and Administration) Rules, 2014, the Company has fixed **Saturday, September 19, 2026** as the cut-off date for the purpose of determining the eligibility of shareholders holding shares either in physical or dematerialized form to cast their votes electronically. The e-voting period shall commence from **Wednesday, September 23, 2026 and end on Friday, September 25, 2026.**

e) **Closure of Register of Members and Share Transfer Books**

In compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors approved the closure of the Register of Members and other Transfer Books of the Company from **Saturday, September 19, 2026 to Friday, September 25, 2026 (both days inclusive)**, in connection with the proposed payment of final Dividend @ **10% i.e. Re. 1/- per Equity Share**, subject to approval of the members at the forthcoming Annual General Meeting.

f) **Taking note of notices/communications received from Stock Exchanges**

The Board took note of the notices/communications received from **BSE Limited and National Stock Exchange of India Limited** (Copy enclosed as **Annexure-C**) in respect of non-compliance/compliance-related matters under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the applicable Standard Operating Procedure/penal provisions prescribed by the Stock Exchanges.

The Board specifically took note of the notice received from **BSE Limited dated May 27, 2026**, regarding fines pursuant to the applicable SEBI Master Circular relating to penal action for non-compliance, wherein the Exchange had observed non-compliance with **Regulation 19(1)/19(2) of the SEBI (LODR) Regulations, 2015** relating to inclusion of an Executive Member instead of Non-Executive Member in the constitution of the Nomination and Remuneration Committee, and levied a basic fine of **₹94,000 plus GST of ₹16,920**, aggregating to **₹1,10,920.**

The Board also took note of the communication received from **National Stock Exchange of India Limited** in relation to listing fine fees for non-compliance with the applicable requirements, involving a basic fine of **₹94,000 plus IGST of ₹16,920**, aggregating to **₹1,10,920.**



The payment has been made to both the exchanges on June 02, 2026.

The Board considered the contents of the aforesaid communications and directed the concerned officials of the Company to take necessary corrective and compliance measures and to ensure strict adherence to the applicable provisions of the SEBI (LODR) Regulations, 2015 and the requirements of the Stock Exchanges.

The Board further directed that the necessary actions in respect of the matters referred to in the aforesaid communications be taken within the stipulated timelines and that the requisite responses/remittance/compliance details, wherever applicable, be submitted to the respective Stock Exchanges.

Please note that the reports of Auditors are with unmodified opinion with respect to the Unaudited Financial Results of the Company for the quarter ended June 30, 2026.

The meeting of the Board of Directors commenced at 02.00 p.m. and concluded at 03.15 p.m.

The Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter ended on June 30, 2026, as approved by the Board, will also be available on the Company's website www.medicamen.com.

This is for your information and records.

Thanking You,

Yours faithfully,
For Medicamen Biotech Limited



Parul Choudhary
Company Secretary
ACS44157

PARUL
CHOUH
ARY

Digitally signed
by PARUL
CHOUHARY
Date: 2026.08.14
15:20:29 +05'30'



MEDICAMEN BIOTECH LIMITED

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594

E-mail : cs@medicamen.com, Website: www.medicamen.com

Unaudited Standalone and Consolidated Financial Results for the Quarter ended 30th June'2026

PART I

Particulars	Standalone				Consolidated			
	Three Month Period Ended		Year Ended		Three Month Period Ended		Year Ended	
	30.06.2026 Unaudited	31.03.2026 Audited	30.06.2025 Unaudited	31.03.2026 Audited	30.06.2026 Unaudited	31.03.2026 Audited	30.06.2025 Unaudited	31.03.2026 Audited
1 Income from operations								
(a) Net Sales / Income from operations	4,385.27	5,468.08	3,844.90	17,884.58	4,789.69	6,064.66	4,304.48	19,776.97
(b) Other Income	86.16	171.63	47.03	310.43	86.16	173.52	47.03	311.32
(c) Total Revenue	4,471.43	5,640.71	3,891.93	18,195.01	4,875.85	6,238.18	4,351.50	20,088.29
2 Expenses								
a) Cost of Material Consumed	2,207.52	2,543.12	2,387.78	9,181.38	2,261.07	2,609.29	2,459.77	9,434.81
b) Purchase of Goods Traded	-	-	-	-	-	-	-	-
c) Changes in inventory of Finished Goods and Work in Progress	(149.05)	610.41	(188.49)	742.38	(149.05)	610.41	(188.49)	742.38
d) Employees Benefits Expenses	622.33	624.03	510.53	2,278.67	931.38	939.91	809.03	3,469.31
e) Finance Cost	61.94	59.89	56.24	278.45	82.88	38.30	115.34	349.74
f) Depreciation and Amortisation Expenses	174.38	172.50	177.30	705.87	178.69	173.32	180.13	721.85
g) Other expenses	1,226.12	1,777.81	711.65	3,853.40	1,313.70	1,361.03	762.63	4,171.75
Total Expenses	4,145.69	5,287.76	3,675.00	17,040.23	4,618.68	5,732.21	4,138.41	18,889.85
3 Profit/(Loss) before Exceptional Items & Tax (1-2)	325.79	352.95	216.94	1,154.78	257.17	505.97	213.09	1,198.44
4 Exceptional Items (Commercial Tax Expenses Related to Earlier Years)	-	-	-	-	-	-	-	-
5 Profit/(Loss) before Extra Ordinary Items & Tax (3-4)	325.79	352.95	216.94	1,154.78	257.17	505.97	213.09	1,198.44
6 Tax Expenses								
Current Year	83.01	65.28	56.96	254.83	83.01	65.28	56.96	254.83
MAIT Credit Entitlement	-	-	-	-	-	-	-	-
Deferred Tax Liability	(9.91)	(9.54)	(3.68)	(40.91)	(10.04)	(4.01)	(3.91)	(36.03)
Total Tax Expense	73.10	55.74	53.28	213.92	72.97	61.27	53.05	218.80
7 Net Profit /Loss for the period from Continuing operation (5- 6)	252.69	297.22	163.66	940.87	184.60	444.70	160.05	579.64

R. B. Bhatnagar



Particulars	Standalone				Consolidated			
	Three Month Period Ended		Year Ended		Three Month Period Ended		Year Ended	
	30.06.2026	31.03.2026	30.06.2025	31.03.2025	30.06.2026	31.03.2026	30.06.2025	31.03.2026
	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited
8 Other Comprehensive Income								
Item that will not reclassified to Profit & Loss								
9 Total Comprehensive Income net of Tax	252.69	297.22	153.66	940.87	184.60	444.70	160.45	979.64
10 Net Profit /Loss attributable to								
a) Controlling Interest					211.84	385.71	215.30	964.13
b) Non-controlling Interest					(27.23)	58.99	(55.25)	15.51
11 Paid up equity share capital (Rs. 10/- per share)	1,356.28	1,356.28	1,356.28	1,356.28	1,356.28	1,356.28	1,356.28	1,356.28
12 Earning Per Share (Rs.)								
Basic	1.86	2.19	1.21	6.94	1.36	3.28	1.18	7.22
Diluted	1.86	2.19	1.21	6.94	1.36	3.28	1.18	7.22

NOTES :

- The above un-audited standalone and consolidated financial results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 14, 2026.
- These standalone and consolidated unaudited financial results have been prepared in accordance with recognition and measurement principles of Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and the other accounting principles generally accepted in India.
- The above unaudited standalone and consolidated financial results for the quarter ended June 30, 2026 are prepared in compliance with the Ind AS which have been subjected to a limited review by the statutory auditors of the Company. The statutory auditors have issued limited review reports with unmodified conclusion on the un-audited standalone and consolidated financial results.
- As the Group's business activity falls within a single operating segment viz "Pharmaceutical", no segment information is disclosed.
- Consolidated results of the company includes the results of its subsidiaries i.e., Opal Pharmaceuticals Pty Ltd and Medicamen Life Sciences Private Limited.
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 - "Earning per Share"
- The figures for the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of the full financial year and the published year to date un-audited figures upto the third quarter of the previous financial year, which were subject to limited review.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

Place : New Delhi
Dated : 14.08.2026

For and on behalf of the Board
Medicamen Biotech Limited

R. B. Bishnoi
Rahul Bishnoi
Chairman
(DIN: 00317960)



LIMITED REVIEW REPORT ON UNAUDITED QUARTERLY STANDALONE FINANCIAL RESULTS OF MEDICAMEN BIOTECH LIMITED UNDER REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

To

**The Board of Directors,
Medicamen Biotech Ltd.
1506, Chiranjiv Tower, 43
Nehru Place, New Delhi-110019**

We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Medicamen Biotech Limited ("the Company") for the quarter ended June 30, 2026, together with notes thereon, ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.


This Statement which is the responsibility of the Company's Management and reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 14, 2026, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013, read with relevant Rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Attention is drawn to the fact that the figures for the quarter ended March 31, 2026, as reported in the Statement are the balancing figures between audited figures in respect of the full financial year ended March 31, 2026, and published unaudited year to date figures up to the end of the third quarter of the previous financial year, which were reviewed by us.

For Rai Qimat & Associates
Chartered Accountants



Partner
(Membership Number: 013152C)
UDIN: 26080857SAUSU6691

Place: Gurugram
Date: 14.08.2026

LIMITED REVIEW REPORT ON UNAUDITED QUARTERLY CONSOLIDATED FINANCIAL RESULTS OF MEDICAMEN BIOTECH LIMITED UNDER REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

To

The Board of Directors,
Medicamen Biotech Ltd.
1506, Chiranjiv Tower, 43
Nehru Place, New Delhi-110019

We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Medicamen Biotech Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2026, together with the notes thereon, ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Parent's Management and reviewed by the Parent's Audit Committee and approved by the Parent's Board of Directors at their respective meetings held on August 14, 2026, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act"), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", Issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities:

- a. Opal Pharmaceuticals Pty Ltd (Wholly Owned Subsidiary Company)
- b. Medicamen Life Sciences Private Limited (Subsidiary Company)

Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6(a) below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We did not review the interim financial information of subsidiaries included in the Statement, whose interim financial information reflects total revenues of Rs. 404.42 lakh, total net profit after tax of Rs. (68.90) lakh, total comprehensive income is Nil for the quarter ended June 30, 2026, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Parent's Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

Attention is drawn to the fact that the figures for the quarter ended March 31, 2026, as reported in the Statement are the balancing figures between audited figures in respect of the full financial year ended March 31, 2026, and published unaudited year to date figures up to the end of the third quarter of the previous financial year, which were reviewed by us.

For Rai Qimat & Associates
Chartered Accountants


Qimat Rai Garg
Partner

(Membership Number: 013152C)

UDIN: 26080857111133281

Place: Gurugram

Date: 14.08.2026

National Stock Exchange of India

NSE/LIST-SOP/COMB/FINES/0611

May 27, 2026

To,
The Company Secretary
Medicamen Biotech Limited

Dear Sir/Madam,

Subject: Notice for non-compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Your attention is drawn towards SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 ("Master Circular") issued on July 11, 2023 and last updated on January 30, 2026 (hereinafter referred to as "Master Circular"), specifying Standard Operating Procedure for imposing fines and suspension of trading in case of non-compliance with the Listing Regulations. On verification of the Exchange records, it has been observed that your Company has not complied/delayed complied with certain Listing Regulation(s). The details of non-compliance(s)/delayed compliance(s), total fine payable by your Company and the particulars about manner in which fine should be remitted to the Exchange is enclosed as **Annexure**.

You are requested to inform the Promoters about identified non-compliance/delayed compliance and to ensure compliance with respective regulation(s) and make the payment of fines within 15 days from the date of this notice, failing which the Exchange may initiate following actions as per Master Circular:

1. Initiate freezing of entire shareholding of the Promoters in the Company as well as in other securities held in the Demat account of the Promoters.
2. Trading in securities of your Company shall take place on a 'Trade for Trade' basis, in case of consecutive default with Regulations 17(1), 18(1) and 27(2) of the Listing Regulations i.e., Shifting of trading in securities to Z Category as per Master Circular.

Upon receipt of this review notice, the Company may file the waiver request. Below are the parameters for filing the application for waiver:

- a) Waiver applications sent via mail is not considered. The Company is requested to submit waiver application on the below mentioned path:

NEAPS>>Compliance>>Fine Waiver>>Waiver Request.

- b) Detailed submission indicating reasons for waiver, mentioning whether it intends to seek personal hearing before the concerned Committee.

- c) Further, **compliance is a pre-requisite for applying for waiver**. Thus, waiver application of the non-complied Companies will not be processed without achieving the compliance.

This document is digitally signed by

National Stock Exchange Of India Limited

d) In case the Company is non-compliant under multiple regulations, the Company is advised to file a single application mentioning the details of all the respective regulations and quarters for which the Company intends to apply for waiver.

e) **Non-refundable** Processing fees for an amount of Rs.10,000 plus 18% GST to be paid to the designated Exchange, (as segregated between the Exchanges as per the policy for waiver of fines) only if the fine amount is more than Rs. 5,000/- exclusive of GST.

However, before filing an application for waiver of fines, you are requested to refer to the below policy available on the Exchange's website. For ready reference you may refer below link:

Policy on processing of waiver application:

https://nsearchives.nseindia.com/web/circular/2026-01/Policy_for_waiver_of_fines_Final_20260113193131.pdf

Further, as per Master Circular, your Company is also required to ensure that the said non-compliance which has been identified by the Exchange and subsequent action taken by the Exchange in this regard shall be placed before the Board in the next Board Meeting and comments made by the Board shall be duly informed to the Exchange at the below mentioned path in NEAPS portal along with this letter for dissemination having the announcement text as 'Board comments on fine levied by the Exchange'

Path: NEAPS > COMPLIANCE > Announcements > Announcements/ CA (Subject: Updates)

In case of any clarification, you may send an email on listingsop@nse.co.in or contact any of the below mentioned Exchange Officers from Listing Compliance Department:

Ms. Madhu Kadam
Ms. Harshita Chaubal
Ms. Duhita Dhure
Ms. Suman Lahoti
Ms. Chanchal Daga (Waiver request)
Ms. Sweety Mamodia (Waiver request)

Yours faithfully,

For National Stock Exchange of India Limited

Sonam Yadav
Manager

This document is digitally signed by

Parul

From: bse.soplodr <bse.soplodr@bseindia.com>
Sent: 27 May 2026 16:59
To: cs@medicamen.com; cs@medicamen.com; cs@medicamen.com
Cc: bse.soplodr
Subject: 531146-Fines as per SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 issued on July 11, 2023 and last updated on January 30,2026 (Chapter VI (A)-Penal Action for Non-Compliance)

Ref.: SOP-Review letter

To
The Company Secretary/Compliance Officer
Company Name: Medicamen Biotech Ltd
Scrip Code: 531146

Dear Sir/Madam,

Sub: Fines as per SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 issued on July 11, 2023 and last updated on January 30,2026 (Chapter VII (A)-Penal Action for Non-Compliance).

The company is advised to refer to the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 issued on July 11, 2023 and last updated on January 30,2026 issued by Securities and Exchange Board of India (SEBI) with respect to penal actions prescribed for non-compliance of certain provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the Standard Operating Procedure for suspension and revocation of trading of specified securities of listed entities.

The Exchange had also issued a guidance note regarding the provisions of the said SEBI circular which is disseminated on the Exchange website at the following link:

https://www.bseindia.com/downloads/Guidance_Note_for_SEBI_SOP_Circular.pdf

In this regard it is observed that the company is non-compliant/late compliant with the following Regulations for the period mentioned below:

Applicable Regulation of SEBI (LODR) Regulations, 2015	Fine prescribed	Fines levied for quarter ended	Fine payable by the company as on May 27,2026 (inclusive of GST @ 18 %)		
			Basic Fine	GST @ 18 %	Total Fine payable

Regulation 17(1) Non-compliance with the requirements pertaining to the composition of the Board including failure to appoint woman director	Rs. 5,000 per day	-	0	0	0
Regulation 17(1A) Non-compliance with the requirements pertaining to appointment or continuation of Non-executive director who has attained the age of seventy-five years	Rs. 2,000 per day	Mar-26	0	0	0
Regulation 17(2) Non-compliance with the requirements pertaining to the number of	Rs. 10,000 per instance	Mar-26	0	0	0

Board meetings					
Regulation 17(2A) Non-compliance with the requirements pertaining to quorum of Board meetings.	Rs. 10,000 per instance	Mar-26	0	0	0
Regulation 18(1) Non-compliance with the constitution of audit committee	Rs. 2,000 per day	Mar-26	0	0	0
Regulation 19(1)/ 19(2) Non-compliance with the constitution of nomination and remuneration committee	Rs. 2,000 per day	Mar-26	94000	16920	110920
Regulation 20(2)/(2A) Non-compliance with the constitution of stakeholder relationship committee	Rs. 2,000/- per day	Mar-26	0	0	0

Regulation 21(2) Non-compliance with the constitution of risk management committee	Rs. 2,000/- per day	Mar-26	0	0	0
Regulation 27(2) Non-submission of the Corporate governance compliance report within the period provided under this regulation	Rs. 2,000/- per day	Mar-26	0	0	0
		Total	94000	16920	110920

The Company is therefore advised to note that as per the provisions of this circular:

- The company is required to ensure compliance with above regulation and ensure to pay the aforesaid fines including GST within 15 days from the date of this letter/email, failing which Exchange shall, pursuant to the provisions of the aforesaid circular, initiate action related to freezing of the entire shareholding of the promoter in this entity as well as all other securities held in the demat account of the promoter.
- Further in the event of this being the second consecutive quarter of non-compliance for the Regulation 17(1), 18(1), 27(2) would result in the company being transferred to Z group and liable for suspension of trading of its equity shares.
- The company is also advised to ensure that the subject matter of non-compliance which has been identified and indicated by the Exchange and any subsequent action taken by the Exchange in this regard shall be placed before the Board of Directors of the company in its next meeting. Comments made by the board shall be duly informed to the Exchange for dissemination.

For the Companies to whom Regulation 15 (2) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, is not applicable, a certificate from the Company Secretary/Compliance Officer of the company, certifying that Paid up equity capital was not exceeding Rs.10 Crores and Net worth was not

exceeding Rs.25 Crores as on the last day of the previous three consecutive financial year is required to be submitted to the Exchange. Companies are required to mention the exact paid up equity capital and net worth figures in this certificate.

Provided that where the provisions of the regulations specified in the regulation becomes applicable to a listed entity at a later date, such listed entity shall comply with the requirements of those regulations within six months from the date on which the provisions become applicable to the listed entity.

Provided further that once the above regulations become applicable to a listed entity, they shall continue to remain applicable till such time the equity share capital or the net-worth of such entity reduces and remains below the specified threshold for a period of three consecutive financial years.

(For XBRL related queries company may contact on helpline no: 9316749660 or send emails to query.lodr@bseindia.com). The Excel utility of Integrated Governance Report can be downloaded from the Listing Centre portal.

Yours faithfully

Reena Raphael
Manager
Listing Compliance

Shraddha Bagwe
Deputy Manager
Listing Compliance

In case of any further queries please email the following ids:

Particulars	Email Id	Contact Number
Query on compliance of Reg 17 to 21,27	Shraddha.Bagwe@bseindia.com Sagar.Darra@bseindia.com cgcompliances@bseindia.com	022-22728148/5833/8087
Query on remittance	bse.soplodr@bseindia.com	022-22728194

Company is requested to remit the fine amount to the following designated **VIRTUAL BANK ACCOUNT** of the Exchange.

Company Name	Medicamen Biotech Ltd		
Account Name	Bank Name & Branch	Virtual Bank Account No.*	IFSC Code
BSE Limited	ICICI Bank Ltd.- CMS Branch	BSER06890	ICIC0000104

**Note: This bank account is specifically dedicated to SOP fine and Waiver fees only, Therefore, company is advised not to deposit/credit any amount payable other than SOP fines/penalties/waiver.*

The company is required to submit fine remittance details in the following format given at Annexure I to Email id: bse.soplodr@bseindia.com

Annexure-1 (On letterhead of the company)

Sub: Details of Payment of fines for Non-Compliance with Regulations of SEBI (LODR) Regulations, 2015:

Remittance details:

Scrip Code	Regulation & Quarter	Bank UTR number	Date of Payment	Amount paid	TDS deducted, if any	Net Amount paid

This mail is classified as **Internal** by Reena Raphael on May 27, 2020 at 10:59:05